Ascentage Pharma Group International (HKG:6855)
29.96
+0.10 (0.33%)
Nov 10, 2026, 4:08 PM HKT
HKG:6855 Revenue
Ascentage Pharma Group International had revenue of 302.21M CNY in the half year ending June 30, 2026, a decrease of -63.31%. This brings the company's total for the last twelve months to 642.64M, up 64.52% year-over-year. In the year 2025, Ascentage Pharma Group International had annual revenue of 574.12M, down -41.46%. That makes Ascentage Pharma Group International the 23,107th largest company in the world by revenue and 1,364th in Hong Kong.
Revenue (ttm)
642.64M CNY
Revenue Growth
+64.52%
P/S Ratio
14.87
Revenue / Employee
776.13K CNY
Employees
828
Market Cap
11.02B HKD
Revenue by Geography
- Switzerland 678.42M 69.2%
- Chinese Mainland 302.24M 30.8%
Fiscal year ended Dec 31, 2024 See the full HKG:6855 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 574.12M | -406.53M | -41.46% |
| Dec 31, 2024 | 980.65M | 758.67M | 341.77% |
| Dec 31, 2023 | 221.98M | 12.27M | 5.85% |
| Dec 31, 2022 | 209.71M | 181.80M | 651.38% |
| Dec 31, 2021 | 27.91M | 15.46M | 124.18% |
| Dec 31, 2020 | 12.45M | -2.06M | -14.21% |
| Dec 31, 2019 | 14.51M | 7.71M | 113.21% |
| Dec 31, 2018 | 6.81M | 479.00K | 7.57% |
| Dec 31, 2017 | 6.33M | -1.34M | -17.46% |
| Dec 31, 2016 | 7.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Everest Medicines | 2.78B |
| Shanghai Haohai Biological Technology | 2.64B |
| HBM Holdings | 1.40B |
| Duality Biotherapeutics | 972.22M |
| Suzhou Ribo Life Science | 536.18M |
| CStone Pharmaceuticals | 490.92M |
| Metis TechBio | 298.03M |
| Nanjing Leads Biolabs | 246.16M |
Ascentage Pharma Group International News
- 5 days ago - Ascentage Pharma to Present Data from Multiple Trials, Including an Oral Presentation of APG-5918 at ASH 2026 - GlobeNewsWire
- 6 days ago - Ascentage Pharma to Participate in Two Upcoming Investor Conferences in London - GlobeNewsWire
- 20 days ago - Ascentage Pharma's Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL - GlobeNewsWire
- 25 days ago - Ascentage Pharma initiated with an Outperform at William Blair - TheFly
- 27 days ago - Ascentage Pharma initiated with a Buy at Citi - TheFly
- 4 weeks ago - Ascentage Pharma initiated with an Outperform at Citizens - TheFly
- 4 weeks ago - 3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead - MarketBeat
- 4 weeks ago - Ascentage Pharma price target lowered to $33 from $46 at JPMorgan - TheFly